جستجوی استاد راهنمای دانشگاهی

Rotem Karniمشاهده پروفایل

دانشیار

• Alternative RNA Splicing
• RNA Biology
• Cancer Therapy
• +۴ مورد دیگر

Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu

Outi Salo-Ahenمشاهده پروفایل

مدرس ارشد

• Pharmaceutical Chemistry
• Molecular Modeling
• Drug Design
• +۵ مورد دیگر

Senior Lecturer Outi Salo-Ahen is affiliated with Åbo Akademi University's Faculty of Natural Sciences and Engineering , Department of Pharmacy. Her research focuses on computational pharmacology, drug design, and pharmaceutical chemistry, particularly targeting chemokine receptors (CCR5/CXCR4) and transient receptor potential channels (TRPA1) for therapeutic applications. Doctor of Pharmacy (2006, University of Kuopio/UEF) MSc in Pharmaceutical Chemistry (2001, UEF) BSc in Pharmacy (1999, UEF) University Pedagogy Modules 1-5 (2012-2015) Her work contributes to UN Sustainable Development Goals through education and pharmaceutical innovation . Recent research trends include: Antimicrobial resistance solutions TRPA1 channel modulation Nanotechnology-enabled drug delivery Multi-target HIV-1 inhibitors 3D printing of biocompatible materials Computational analysis of nucleic acid frameworks She actively supervises doctoral projects, serves on assessment panels, and leads collaborations like Nordic Pharmaceutical Translation and Innovation. Her 60+ publications demonstrate expertise in molecular modeling and drug discovery.

Alicia Cheمشاهده پروفایل

استادیار

• Neuroscience
• Developmental Neuroscience
• Behavioral Neuroscience
• +۵ مورد دیگر

Alicia Che is an Assistant Professor of Psychiatry at Yale University School of Medicine and serves as Director of Graduate Admissions for the Interdepartmental Neuroscience Program. She joined the Yale Department of Psychiatry in 2021 after completing her postdoctoral fellowship with Dr. Natalia De Marco García at Weill Cornell Medical College and Dr. Gord Fishell at NYU. Her research is conducted through the Che Lab at Yale, where she investigates how early life experiences impact brain circuit assembly and mature function in models of psychiatric illness. Yale School of Medicine, Department of Psychiatry Interdepartmental Neuroscience Program Center for Brain & Mind Health Division of Molecular Psychiatry Wu Tsai Institute Yale Center for the Science of Cannabis and Cannabinoids Dr. Che earned her Ph.D. in Physiology and Neurobiology from the University of Connecticut in 2014, where she worked in the laboratory of Dr. Joseph LoTurco. She received her B.S. with triple majors in Biology, Physics, and Physical Chemistry from Pacific Lutheran University in Washington state in 2009. Her research focuses on understanding developmental trajectories following early life experiences to develop diagnostics and early interventions for psychiatric illnesses. Dr. Che's research examines how sensory inputs, social bonding, stress, and substance exposure impact brain development. She employs a multi-dimensional approach to assess transcriptional, circuit, neuronal activity, and behavioral changes across the entire developmental timeline. Her lab currently focuses on four specific areas: the role of oxytocin in social behavior development, circuit dysfunction in PTSD, early-life cannabinoid exposure effects, and the impact of early life stress on development and adulthood. She utilizes advanced techniques including mouse genetics, slice electrophysiology, and longitudinal in vivo 2-photon imaging on behaving animals. Her most recent publications demonstrate significant contributions to understanding neural circuit development, PTSD mechanisms, and the effects of early life experiences on brain function. Her work spans from molecular neuroscience to behavioral outcomes, with publications in top journals including Nature, Neuron, and Nature Communications. Her research has revealed important insights into how translaminar neuronal activity strengthens cortical columns, how oxytocin facilitates social touch development, and how PTSD affects brain transcriptomics. NARSAD Young Investigator Award (2020) K99/R00 Pathway to Independence Award from NINDS (2019) Dr. Che's work has significant implications for understanding and treating neurodevelopmental disorders, PTSD, and the consequences of early life experiences on mental health. She collaborates extensively with researchers across Yale and beyond, with frequent co-authorship with colleagues including Lin Lin, Alex Kwan, and Christopher Pittenger. Her research program bridges basic neuroscience with clinical applications, aiming to translate findings into potential interventions for psychiatric conditions.

• Cerebral Microcirculation
• Vascular Biology
• Endothelial Cell Function
• +۶ مورد دیگر

William Mayhan is a Professor in Biomedical Sciences at the University of South Dakota . His research focuses on cerebral microcirculation and vascular biology , particularly examining endothelial cell function in disease states like diabetes and alcohol consumption. Education: PhD in Biomedical Sciences, University of Nebraska Medical Center (1983) Post-Doctoral Fellowship, University of Iowa (1985) BS in Biology, Creighton University (1977) His work investigates blood-brain barrier permeability and cerebral vasculature responses to hypertension, diabetes, and alcohol. Key findings include mechanisms of nitric oxide synthase (NOS) dysfunction and oxidative stress in diabetic and alcoholic models. Recent publications analyze prenatal alcohol exposure effects on cerebral arterioles and CB2 receptor agonists for vascular protection in diabetes. His studies span in vivo models, potassium channel dynamics , and inflammatory mediators in stroke pathogenesis.

Graham Laddsمشاهده پروفایل

استاد

• Pharmacology
• G protein-coupled receptors
• Signal Bias
• +۵ مورد دیگر

Professor Graham Ladds is a Professor of Receptor Pharmacology at the University of Cambridge's Department of Pharmacology and Fellow of St John's College. He serves as Co-Director of the Cambridge Academy of Therapeutic Science and Director of Studies for Pharmacology. His academic journey includes a BSc in Biochemistry from the University of Birmingham and PhD in yeast pheromone signalling from the University of Warwick, where he progressed to Associate Professor before joining Cambridge in 2015. His research focuses on G protein-coupled receptor (GPCR) pharmacology, specializing in: Agonist bias mechanisms and signaling dynamics Mathematical modeling of receptor-ligand interactions RAMPs (Receptor Activity-Modifying Proteins) in Class B1 GPCRs Intracellular calcium signaling pathways Development of biosensors for receptor activity screening He employs multidisciplinary approaches combining pharmacological assays, computational modeling, and machine learning. His recent publications demonstrate strong focus on adenosine receptor pharmacology, GPCR signaling bias, and therapeutic applications for metabolic/cardiovascular disorders. Research frequently appears in high-impact journals with significant industry collaboration themes. Honors include: Fellow of the British Pharmacological Society (2020) Royal Society Industry Fellowship for collaboration with AstraZeneca He leads a 17-member research group investigating GPCR signaling dynamics and maintains active industry partnerships with GSK, Takeda, and AstraZeneca. His teaching includes lectures on drug-receptor interactions and diabetes therapeutics for medical/natural sciences students. Laboratory activities focus on: BRET-based molecular probing of GPCR interactions Development of computational models for receptor activation Calcium signaling studies continuing legacy of Professor Colin Taylor Industry-linked drug discovery projects

Xi-Long Zhengمشاهده پروفایل

استاد

• Vascular Smooth Muscle Biology
• Atherosclerosis
• Vascular Disease Mechanisms
• +۴ مورد دیگر

Xi-Long Zheng is a tenured Professor in the Department of Biochemistry and Molecular Biology and Department of Physiology and Pharmacology at the Cumming School of Medicine, University of Calgary. He holds additional appointments as a Member of the Libin Cardiovascular Institute and Associate Member of both the Snyder Institute for Chronic Diseases and Arnie Charbonneau Cancer Institute. His research focuses on vascular smooth muscle biology and its role in cardiovascular diseases. Doctor of Medicine, Hunan Medical University (1986) M.S. in Pharmacology, Hunan Medical University (1989) Doctor of Philosophy in Pharmacology, University of Calgary (1997) Dr. Zheng's research centers on vascular smooth muscle cell differentiation, proliferation, and phenotypic switching in vascular diseases. His laboratory investigates mechanisms of vascular smooth muscle dedifferentiation in atherosclerosis, abdominal aortic aneurysms, and vascular stiffness. Current work explores ferroptosis, epigenetic regulation (particularly BRD4), and PCSK9 functions in vascular pathologies. His studies integrate molecular, cellular, and in vivo approaches to identify novel therapeutic targets for cardiovascular diseases. Analysis of his recent publications reveals strong emphasis on cell death mechanisms (ferroptosis, cuproptosis), epigenetic regulation, lipid metabolism, and immune-vascular interactions in atherosclerosis. His work demonstrates increasing focus on translational applications targeting vascular smooth muscle phenotypic switching and plaque stability. Alberta Innovates ‒ Health Solutions Senior Scholar Award (2008-2015) Heart & Stroke Foundation New Investigator Award (2001-2006) CIHR/Hypertension Society Scholarship Award (2001-2004) Heart & Stroke Foundation Fellowship Award (1999-2001) AHFMR Independent Investigator Award (2008) Dr. Zheng serves on grant panels for Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada. He is an editorial board member for Biochemical Journal and other scholarly publications. His laboratory receives funding from CIHR and NSERC for projects including smooth muscle PCSK9 in abdominal aortic aneurysm pathogenesis, smooth muscle autophagy in vascular aging, and epigenetic regulation of smooth muscle plasticity. The Zheng Lab investigates vascular smooth muscle functions across multiple organ systems including blood vessels, gastrointestinal tract, bladder, and uterus. His research has established critical mechanisms in vascular smooth muscle differentiation and cell cycle regulation, contributing over 100 peer-reviewed publications in high-impact journals including PNAS, ATVB, Diabetologia, JBC, and Hypertension.

Michael D. Burtonمشاهده پروفایل

دانشیار

• Neuroimmunology
• Pain Management
• Metabolic Disorders
• +۵ مورد دیگر

Dr. Michael D. Burton is an **Associate Professor** and **Eugene McDermott Distinguished Professor** in the Department of Neuroscience at the University of Texas at Dallas (UT Dallas), affiliated with the **School of Behavioral and Brain Sciences**. He is a founding member of the **Center for Advanced Pain Studies (CAPS)** and holds roles in the **Center for Vital Longevity (CVL)**. His research focuses on neuroimmunology, pain mechanisms, and metabolic disorders, emphasizing how immune-nervous system interactions influence chronic pain, depression, anxiety, and aging-related conditions. Dr. Burton’s work bridges preclinical and translational research, using rodent models and human clinical samples. Education: PhD in Animal Science (Immunophysiology and Behavior), University of Illinois at Urbana-Champaign (2012) B.S. in Animal Science and Biotechnology, University of Illinois at Urbana-Champaign (2006) Postdoc in Pain Neurobiology, UT Dallas (2017) Postdoc in Diabetes/Metabolism Research, UT Southwestern Medical Center (2015) Research Interests: Dr. Burton investigates how peripheral stimuli (diet, alcohol, immune activation) affect pain and behavior through neuroimmune pathways. Key areas include: Sex differences in pain sensitivity and neuroinflammation Risk factors for chronic pain (e.g., high-fat diets, aging) Neuroimmune biomarkers for pain and delirium Development of non-opioid analgesics (e.g., cannabinoids) Awards: 2024 ROAR Research Award, UT Dallas 2023 Eugene McDermott Distinguished Professorship 2022 SFNova/Rising Star (Society for Neuroscience) 2019 Mitchell Max Award for Pain Research Grants & Leadership:** Co-Director, **Enhancing Neuroscience Undergraduate Research Experiences (ENSURE)** program ($900K grant) NIH R35, R21 grants (pain and metabolism) Editorial roles: *Neurobiology of Pain*, *Journal of Neuroinflammation*, and others Labs & Teams:** Neuroimmunology and Behavior Lab (UT Dallas) Member, NIH Pain Consortium and Endocrine Society’s Basic Science Group

Ganesh Thakurمشاهده پروفایل

استاد

• Small Molecule Medicinal Chemistry
• Drug Discovery Methodologies
• Cannabinoid Receptor Modulation
• +۵ مورد دیگر

Dr. Ganesh Thakur is a Full Professor and Chair of the Department of Pharmaceutical Sciences at Northeastern University. He holds a PhD in Organic Chemistry from the Institute of Chemical Technology, Mumbai, and has held roles from Senior Scientist to tenured Professor since 2004. His research focuses on cannabinoid receptor modulation, nicotinic acetylcholine receptors, and AI-driven drug discovery. Education: PhD, Organic Chemistry, Institute of Chemical Technology (ICT), Mumbai, India MS, Chemistry, Indian Institute of Technology (IIT), Mumbai BS, Chemistry, University of Mumbai Research Interests: Dr. Thakur pioneers small molecule therapeutics targeting cannabinoid receptors (CB1/CB2), nicotinic receptors (α4β2, α7, α9), and GIRK channels. His work addresses epilepsy, glaucoma, neurodegeneration, neuropathic pain, and substance use disorders. He has developed novel allosteric modulators with preclinical efficacy in pain, addiction, and neuroprotection. Grants: Active grants include NIH/NIGMS (Targeting α7 nAChR), Canadian Institutes of Health Research (CB1 PAMs for infantile spasms), and NIH/NHLBI (GIRK channel regulation). Awards: Recipient of 2023 Distinguished Mentor Award, Hind Rattan Award, and multiple RISE Awards for student mentorship. Notable honors include the 2018 Best Patent Award (US Patent #9,926,275 B2) and NIDA Early Career Award (2009). Labs/Teams: Leads the Cannabinoid and Nicotinic Receptor Research Group at Northeastern's Center for Drug Discovery, focusing on translational drug development for CNS disorders.

Steven Lavioletteمشاهده پروفایل

استاد

• Neuropsychiatry
• Addiction Neuroscience
• Neuropharmacology
• +۹ مورد دیگر

Steven Laviolette is a Professor in the Department of Anatomy and Cell Biology at the Schulich School of Medicine and Dentistry, University of Western Ontario. He holds a Ph.D. and B.Sc. from the University of Toronto. His laboratory investigates neuropsychiatric disorders (addiction, depression, schizophrenia, PTSD, anxiety) through neuropharmacology and neurodevelopment, focusing on cannabinoids, opioids, and nicotine. Key research areas include molecular signaling in prefrontal cortex-amygdala-hippocampus circuits, neurodevelopmental impacts of adolescent drug exposure, and therapeutic applications of phytocannabinoids like CBD. Research explores how THC and CBD modulate emotional processing, opioid/nicotine addiction mechanisms, and long-term neuroadaptations from developmental drug exposure. Articles reveal consistent themes: cannabinoid interactions with dopaminergic/serotonergic systems, fear/aversion memory pathways, and prefrontal cortical dysfunction in psychiatric disorders. Neurodevelopmental studies highlight persistent anxiety/depression phenotypes from adolescent nicotine or THC exposure. C.I.H.R. New Investigator Fellowship Early Researcher Award (Ontario) Young Investigator Award (N.A.R.S.A.D) New Investigator Award (Canadian Psychiatric Research Foundation) Leader’s Opportunity Fund (Canada Foundation for Innovation) Faculty Scholar's Award (Western Ontario) Laviolette mentors 25+ graduate students and 17 postdoctoral researchers, directing a lab with collaborations across Western Ontario departments (Psychiatry, Physiology, Chemistry). He serves on CIHR review panels and the Canadian Institute for Military/Veteran’s Health Research, previously chairing the Ontario Mental Health Foundation review committee.

• Medicinal Chemistry
• Molecular Pharmacology
• Neuroscience
• +۵ مورد دیگر

Professor Mary Collins is a Professor of Pharmaceutical Neuroscience at the University of Sydney , affiliated with the Sydney School of Medical Sciences . She serves as Interim Associate Dean, Research and Head of School . Member of the Centre for Drug Discovery Innovation Member of the Brain and Mind Centre Research Interests GABA Receptors : Focus on subtype-selective modulators, binding site identification, and roles in anxiety, sleep disorders, and epilepsy. Nicotinic Acetylcholine Receptors : Structure-function studies using site-directed mutagenesis and reactive probes to understand ligand binding. Drug Discovery : SAR studies for selective agents targeting Cys-loop receptors, including flavonoids and cannabinoids. Scientific Contributions Her 15 most recent articles (2020-2024) span epilepsy genetics , receptor stoichiometry , neuroprotective flavonoids , and cannabinoid interactions . Key themes include precision medicine for receptor variants and neurotransmitter modulation in disorders. ASCEPT Young Investigator Award RACI Biota Award Fellow of RACI (2006) Supervision Award (University of Sydney, 2008) Advising Current students: Jacinda HOLTSMARK (epilepsy neurophysiology), Sze Hon KAN (genetic epilepsies), Fiona WANG (neurological mechanisms).

Xiaowen Baiمشاهده پروفایل

استاد

• Stem Cell Biology
• Neurodegeneration
• Cardiotoxicity
• +۵ مورد دیگر

Xiaowen Bai, MD, PhD, is a Professor in the Department of Cell Biology, Neurobiology and Anatomy at the Medical College of Wisconsin. His research focuses on leveraging stem cells to model neurodegenerative diseases and cardiac disorders, with a particular emphasis on non-coding RNAs, mitochondria, and environmental stressors like anesthetics and alcohol. He holds a leadership role as Executive Director of Hematology at the World Federation of Chinese Medicine Societies (WFCMS). Education: MD, Shanxi Medical University (1993) PhD, Beijing University Stem Cell Center (2004) Postdoctoral Training, University of Texas MD Anderson Cancer Center (2007) Research Interests: Neurodegeneration mechanisms involving microRNAs, lncRNAs, and mitochondrial dysfunction Stem cell-based therapies for myocardial regeneration Diabetic cardiomyopathy pathogenesis and cardioprotection 3D organoid models for studying anesthetic and alcohol neurotoxicity Recent Work: Recent publications emphasize translational studies using human-induced pluripotent stem cell (iPSC)-derived models to investigate alcohol-induced brain injury, anesthetic neurotoxicity, and cardiac fibrosis. His lab also explores immunomodulatory pathways and redox signaling in inflammatory diseases. Labs/Teams: The Bai Lab develops novel in vitro models for disease modeling and drug testing, focusing on cerebral organoids and cardiac organoids to bridge basic research and clinical applications.

David Nataleمشاهده پروفایل

دانشیار

• Cell Biology
• Regenerative Medicine
• Stem Cell Biology
• +۴ مورد دیگر

Dr. David Natale is an Associate Professor in the Department of Obstetrics and Gynaecology at Queen's University, with a cross-appointment in the Department of Biomedical and Molecular Sciences. His research focuses on placental development, particularly in pregnancies complicated by maternal disease (e.g., pre-eclampsia, diabetes) or exposures (e.g., cannabis). He uses mouse and rat models to study trophoblast stem cell differentiation and placental dysfunction. Education: Ph.D. in Physiology and Pharmacology (University of Western Ontario, 2003), B.Sc. (University of Western Ontario, 1996). Postdoctoral training under Dr. Jay Cross (University of Calgary) and later appointments include Assistant Professor roles at the University of Calgary (2008–2013) and University of California San Diego (2013–2019). Research interests span cell biology, regenerative medicine, and placental biology. His lab investigates how trophoblast populations and interactions are altered under compromised conditions, with recent emphasis on cannabinoid effects and maternal-fetal outcomes. Grants and funding include support from CIHR, NIH/NICHD, and UCSD/UCLA Diabetes Research Center. Current supervision includes postdoctoral fellow Samantha Benton. Labs/Teams: Queen's University placental research group, collaborations with human placenta research teams.

Rainer Spanagelمشاهده پروفایل

استاد

• Addiction Research
• Neuropharmacology
• Translational Medicine
• +۶ مورد دیگر

Prof. Dr. Rainer Spanagel serves as the Head of the Institute of Psychopharmacology at the Central Institute of Mental Health (ZI) within the Medical Faculty Mannheim of Heidelberg University. His research focuses on addiction neuroscience, particularly alcohol and drug dependence, with a strong emphasis on translational approaches bridging preclinical and clinical research. Key areas include comorbid psychiatric disorders (anxiety, depression, ADHD), neurobiological mechanisms of relapse, and the development of novel therapeutic interventions. Spanagel's work utilizes advanced methodologies such as transgenic animal models, neuroimaging (MRI/fMRI), and systems medicine approaches. He leads projects on epigenetic modulation (e.g., oxytocin in alcohol addiction), drug repurposing (psilocybin), and the impact of adverse childhood experiences on addictive behaviors. Major grants include EU NEURON, BMBF (AERIAL, Target-OXY), and DFG funding for systems medicine and single-cell sequencing studies. His research integrates genetic, environmental, and neurochemical factors to address addiction's biological underpinnings. Notable contributions include identifying hyperdopaminergic states in alcohol abstinence and the role of RasGRF2 in cocaine reward pathways. Current initiatives focus on precision medicine strategies for substance use disorders through multi-omics integration and behavioral monitoring. Key Research Themes: Translational addiction, neuropharmacology, comorbidity mechanisms, epigenetics. Collaborations: Pharmaceutical industry partnerships for preclinical drug trials, multi-institutional consortia (SysMedSUDs, TRR265). Facilities: 9.4T MRI for animal neuroimaging, in silico brain banks integrating single-cell omics data.

Rukiyah T. Van Dross-Andersonمشاهده پروفایل

دانشیار

• Cancer Research
• Pharmacology
• Toxicology
• +۷ مورد دیگر

Rukiyah T. Van Dross-Anderson is an Associate Professor and Director of Graduate Programs in the Pharmacology & Toxicology Concentration at East Carolina University's Brody School of Medicine . She holds an Adjunct Professor position in the Department of Chemistry and serves as Advisor for the Summer Biomedical Research Program . Her research focuses on the chemotherapeutic potential of cannabinoids and endocannabinoid metabolites in targeting skin cancer and colorectal cancer through ER stress and oxidative stress pathways. She leads a lab with graduate students, medical students, and research specialists. Education: B.S. in Chemistry, Alabama State University Ph.D. in Molecular and Cellular Pharmacology, Rutgers University/UMDNJ-RWJMS Post-doctoral Fellowship, Vanderbilt-Ingram Cancer Center and University of Kansas Medical Center Her work explores CB1/CB2 receptor-independent mechanisms of endocannabinoids , with a focus on 15dPMJ 2 as a selective antitumor agent. Articles demonstrate its role in DAMP signaling , apoptosis induction , and mitochondrial dysfunction in melanoma and non-melanoma skin cancer. Scientific awards include grants from Golfer’s Against Cancer and East-West Grant . She collaborates with researchers from the Department of Chemistry and Department of Statistics at ECU.

Michael Gajhedeمشاهده پروفایل

استاد

• Protein Crystallography
• Structural Biology
• Drug Design
• +۵ مورد دیگر

Michael Gajhede is a Professor of Protein Crystallography in the Department of Drug Design and Pharmacology at the University of Copenhagen's Faculty of Health and Medical Sciences. With over three decades of academic experience, his career spans from early appointments in the Department of Chemistry to his current position focusing on structural biology and drug design. Dr. Gajhede received his M.Sc. (Cand.scient.) in Chemistry from the University of Copenhagen in 1982 and completed his Ph.D. (Lic.scient.) there in 1986. His research expertise centers on protein crystallography, structural biology, and their applications in medicinal chemistry, particularly in understanding protein-protein interactions and developing novel therapeutic approaches. His recent publications (2023-2025) demonstrate a strong focus on structural approaches to drug discovery, with particular emphasis on protein-protein interaction targets including Keap1-Nrf2 pathway, cannabinoid receptors, and kainate receptors. His work bridges structural biology with practical medicinal chemistry applications, often resulting in novel compounds with therapeutic potential in inflammation, cancer, and neurological disorders. Throughout his career, Gajhede has held significant leadership positions including Chairman of DANSCATT (2008), Chairman of DANSYNC (2004-2007), and various roles in university governance and scientific infrastructure development in Denmark. As an active member of the scientific community, he serves as a referee for international journals in X-ray crystallography, evaluates academic appointments in Denmark, and reviews grant applications for multiple national science foundations across Europe and the United States.